Daniella Beckman's most recent trade in Blueprint Medicines Corp was a trade of 3,902 Common Stock done at an average price of $128.1 . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 128.12 per share. | 18 Jun 2025 | 3,902 | 14,744 (0%) | 0% | 128.1 | 499,924 | Common Stock |
| Upstream Bio Inc. | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 17,096 | 17,096 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.99 per share. | 04 Feb 2025 | 4,284 | 154,232 | - | 3.0 | 12,801 | Common Stock |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 04 Feb 2025 | 3,948 | 150,284 | - | 3.2 | 12,481 | Common Stock |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 156,713 | 156,713 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 26,119 | 158,516 | - | 0 | Common Stock | |
| Upstream Bio Inc. | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 34,681 | 34,681 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 4,570 | 4,570 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,242 | 10,842 (0%) | 0% | 0 | Common Stock | |
| Vor Biopharma Inc | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.56 per share. | 06 Feb 2024 | 1,908 | 134,214 | - | 12.6 | 23,969 | Common Stock |
| Tango Therapeutics Inc | Beckman Daniella | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.62 per share. | 06 Feb 2024 | 1,817 | 132,397 | - | 12.6 | 22,930 | Common Stock |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 236,475 | 236,475 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Beckman Daniella | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 39,413 | 39,413 | - | 0 | Common Stock | |
| Blueprint Medicines Corp | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 2,600 | 8,600 (0%) | 0% | 0 | Common Stock | |
| Vor Biopharma Inc | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 197,051 | 197,051 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 32,842 | 96,709 | - | 0 | Common Stock | |
| Blueprint Medicines Corp | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 2,600 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Vor Biopharma Inc | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Daniella Beckman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2021 | 380,485 | 380,485 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | Daniella Beckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) |